FS Development Corp. II (FSII) to Combine with Pardes Biosciences in $657M Deal
FS II (NASDAQ:FSII) has entered into a definitive agreement to combine with biotech researcher Pardes at an equity value of $657 million. California-based Pardes is developing two pre-clinical drug candidates that have potential treatment applications against COVID-19. The combined company is expected to trade on the Nasdaq under the symbol “PRDS” once the deal closesRead More